Table 1: Baseline demographic and clinical characteristics of AS patients enrolled in ARAD who have been exposed to biological therapy (n = 354)*.

Mean (SD) age, years45.1 (12.3)
Males (%)254 (71.8)
Mean (SD) disease duration, years ( ) 18.5 (12.1)
Mean (SD) delay in diagnosis, years ( ) 5.5 (7.1)
Concomitant DMARDs, (%)72 (20.3)
Methotrexate (oral or IM)50 (14.1)
Salazopyrin22 (6.2)
Leflunomide5 (1.4)
Currently taking prednisolone, (%) 42 (11.9)
Smoking history, (%)
Current 61 (17.2)
Past98 (27.7)
Never195 (55.1)
Alcohol consumption, (%)
Daily 62 (17.5)
Sometimes217 (61.2)
Never75 (21.2)
Mean (SD) ESR, mm/hr ( ) 35.4 (24.8)
Mean (SD) CRP, mg/L ( )31.8 (31.9)
BASDAI (0–10, 0 = best) ( ) 7.6 (4.5)
Mean (SD) S-HAQ score (0–3, 0 no = disability)**0.86 (0.60)
Mean (SD) AQoL score (0-1, 1 = full health)**0.55 (0.25)
SF-36 score**
Physical component36.2 (10.6)
Mental component45.1 (11.1)

*unless otherwise indicated ** in those prior to or within 6 months of commencing bDMARDS